Kappa-Opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of Parkinsonism

Movement Disorders

Volumn 13, Issue 2, 1998, Pages 228-233

  Hughes, Neill R ^a   McKnight, Alexander T ^b   Woodruff, Geoffrey N ^a   Hill, Michael P ^a   Crossman, Alan R ^a   Brotchie, Jonthan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Kappa opioid receptor; Levodopa; Parkinson's disease; Reserpine

Indexed keywords

DOPAMINE; ENADOLINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; LEVODOPA; METIROSINE; MONOAMINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; NORBINALTORPHIMINE; RESERPINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTITUTION THERAPY; SYMPTOM; VOLUNTARY MOVEMENT;

ALPHA-METHYLTYROSINE; ANIMALS; ANTIPARKINSON AGENTS; BENZENEACETAMIDES; BENZOFURANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; LEVODOPA; MALE; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RESERPINE;

EID: 0031951172     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130206     Document Type: Article

References (36)

1. Mitchell IJ, Clarke CE, Boyce S, et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989;32:213-226.
2. Miller WC, Delong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter AB, Jayaraman A, eds. The Basal Ganglia II. New York, NY: Plenum Press, 1987:415-427.
3. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 1991;6:133-138.
4. Reubi JC, Cuenod M. Glutamate release in vitro from corticostriatal terminals. Brain Res 1979;176:185-188.
5. 14C]-GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggests a role for excitatory amino acid but not GABA-mediated transmission in the subthalamic nucleus efferents. Exp Neurol 1991;113:171-181.
6. Klockgether T, Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 1993;34:585-593.
7. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:539-546.
8. Klockgether T, Turski L, Honore T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30:717-723.
9. Locke KW, Holtzman SG. Behavioral effects of opioid peptides selective for μ and δ receptors. II. Locomotor activity in nondependent and morphine-dependent rats. J Pharmacol Exp Ther 1986;238:997-1003.
10. Calenco-Choukroun G, Dauge V, Gacel G, Feger J, Roques BP. Opioid agonists and endogenous enkephalins induce different emotional reactivity than μ agonists after injection in the rat ventral tegmental area. Psychopharmacology 1991;103:493-502.
11. Dauge V, Rossignol P, Roques BP. Comparison of the behavioral effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective μ and δ opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes. Psychopharmacology 1988;96:343-352.
12. Jackson A, Cooper SJ. Observational analysis of the effects of κ opioid agonists on open field behavior in the rat. Psychopharmacology 1988;94:248-253.
13. Goodman RR, Snyder SH. κ-opiate receptors localized by autoradiography to deep layers of cerebral cortex: relation to sedative effects. Proc Natl Acad Sci USA 1982;79:5703-5707.
14. Mulder AH, Burger DM, Wardeh G, Hogenboom F, Frankhuyen AL. Pharmacological profile of various κ-, μ- and δ-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain. Br J Pharmacol 1991;102:518-522.
15. Pinnock RD. Activation of κ-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphe nucleus in vitro. Brain Res 1992;583:237-246.
16. Pinnock RD. A highly selective κ-opioid receptor agonist, CI-977, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro. Neuroscience 1992;47:87-94.
17. McFazdean I, Lacey MG, Hill RG, Henderson G. κ opioid receptor activation depresses excitatory synaptic input to rat locus coeruleus neurons in vitro. Neuroscience 1987;20:231-239.
18. Weisskopf MG, Zalutsky RA, Nicoll RA. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature 1993;362:423-427.
19. Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of κ-opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995;683:102-108.
20. Hill MP, Brotchie JM. Modulation of glutamate release by a κ-opioid receptor agonist in rodent and primate striatum. Eur J Pharmacol 1995;281:R1-R2.
21. 3H]-CI-977: a highly selective ligand for the κ-opioid receptor in both guinea pig and rat forebrain. Molecular Neuropharmacology 1990;1:23-29.
22. 2 opioid receptors. Proc Natl Acad Sci USA 1988;85:4061-4065.
23. Carlsson M, Svensson A. The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci 1990;47:1729-1736.
24. Carlsson M, Svensson A, Carlsson A. Synergistic actions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn Schmeidebergs Arch Pharmacol 1991;343:568-573.
25. Rech RH, Carr LA, Moore KE. Behavioral effects of α-methyltyrosine after prior depletion of brain catecholamines. J Pharmacol Exp Ther 1968;160:326-335.
26. Hunter JC, Leighton KG, Meecham SJ, et al. CI-977, a novel and selective agonist for the κ-opioid receptor. Br J Pharmacol 1990;101:183-189.
27. 3H]- U69,593 A highly selective ligand for the opioid κ receptor. Eur J Pharmacol 1985;109:281-284.
28. Portoghese PS, Lipokowski AW, Takemori AE. Binaltorphimine and NOR-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 1987;40:1287-1292.
29. Carlsson A, Lindqvist M, Magnusson T. 3,4 dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists [Letter]. Nature 1957;180:1200.
30. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a non-indole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109.
31. Manzanares J, Lookingland KJ, Moore KE. Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J Pharmacol Exp Ther 1991;256:500-505.
32. Mitchell IJ, Hughes NR, Carroll C, Brotchie JM. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behavioural Pharmacology 1995;6:492-507.
33. Giuffra M, Mouradian MM, Davis TL, Ownby F, Chase TN. Dynorphin agonist therapy of Parkinson's disease. Clin Neuropharmacol 1994;16:444-447.
34. 2 agonists. Eur J Pharmacol 1991;200:171-173.
35. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by κ opiate receptors. Science 1986;233:774-776.
36. Iwamoto ET. Locomotor activity and antinociception after putative μ, κ and σ opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J Pharmacol Exp Ther 1981;217:451-460.